BMRN — BioMarin Pharmaceutical Share News
0.000.00%
Last trade - 00:00- $10.85bn
- $14.16bn
- $3.22bn
Brief: Biomarin Receives Health Canada Notice Of Compliance With Conditions For Voxzogo®, For Achondroplasia
Brief: BioMarin Announces Proposed Private Offering Of Senior Notes And Syndication Of New Senior Secured Term Loan Facility
U.S. RESEARCH ROUNDUP-Alphabet, Micron Technology, Microsoft
Brief: Biomarin Pharmaceutical Inc - Estimates $3.2 Billion In Total Revenues For FY - SEC Filing
Brief: Veeva And Biomarin Form Long-Term Strategic Partnership
Brief: Veeva And Biomarin Form Long-Term Strategic Partnership
Oppenheimer starts Spruce Biosciences with "outperform" rating on rare disease strength
Australia's Dimerix hits 7-month high on $4.8 billion sale
Deals of the day-Mergers and acquisitions
Deals of the day-Mergers and acquisitions
Brief: Amicus to Pay Biomarin Pharmaceutical $175 Million Merger Termination Fee
Brief: Biomarin To Acquire Amicus Therapeutics For $4.8 Billion
Amicus rises after BioMarin's $4.8 billion buyout deal
BioMarin to acquire Amicus Therapeutics for $4.8 billion (updated)
BioMarin to acquire Amicus Therapeutics for $4.8 Billion
Brief: FDA Accepts Biomarin's Palynziq Supplemental BLA For Priority Review To Expand Use To Adolescents Aged 12-17 With Phenylketonuria
U.S. RESEARCH ROUNDUP- BCB Bancorp, Cadence Design Systems, Intellia Therapeutics
BioMarin Pharma plans to divest struggling gene therapy
Brief: BioMarin Reports Third Quarter 2025 Results And Provides Corporate Update